Chlamydia Trachomatis IgM ELISA Kit

Details for Product No. ABIN459329, Supplier: Log in to see
Chlamydia trachomatis
Kits with alternative reactivity to:
Method Type
Sandwich ELISA
Log in to see
Supplier Product No.
Log in to see
Purpose ELISA-VIDITEST anti-Chlamydia trachomatis IgM is a solid-phase immunoanalytical test.
Sample Type Serum
Analytical Method Qualitative
Detection Method Colorimetric
Specificity 93.3 %
Sensitivity 100 %
Characteristics ELISA-VIDITEST anti-Chlamydia trachomatis IgM kit is intended for the qualitative detection of anti-Mycoplasma pneumoniae antibodies in human serum and human plasma. The laboratory diagnostic procedures in C. pneumoniae infections involve the direct pathogen detection (an isolation of the pathogen, direct antigen detection in cervical, vaginal and urethral swabs or nucleic acid amplification tests from urine - PCR, LCR) and serology tests that reveal specific IgG, IgA and IgM antibodies. Primary chlamydial infection is characterized by the predominant IgM response after 2 to 4 weeks from infection and the delayed IgG and IgA response after 6 to 8 weeks. After the acute C. trachomatis infection IgM antibodies usually decrease and become undetectable in 2 to 6 months. IgG antibody titres decrease slowly, whereas IgA antibodies tend to disappear rapidly When primary chlamydia infection is suspected, the detection of IgM is highly diagnostic. However, in recurrent or chronic infections the prevalence of IgM is low and therefore the absence of IgM does not necessarily exclude an on-going infection. In reinfections, IgG and IgA levels rise quickly. IgA antibodies have shown to be a reliable immunological marker of primary, chronic and recurrent infections. These antibodies usually decline rapidly to baseline levels following treatment and eradication of the chlamydia infection, however may persist for several months. The persistence of the elevated IgA antibody titres is generally considered as the sign of chronic infection. The purified, homogeneous antigen is fixed to each well of the microtiterstrips. Specific antibodies present in the patient's sample are bound during the first incubation step. After removing unbound material by washing, the presence of specific antibodies is detected using anti-human IgM conjugate during the second incubation. The unbound peroxidase conjugate is then removed and TMB substrate is added, resulting in the development of a blue colour. The enzyme reaction is terminated by the addition of a stop solution. The intensity of the colour is proportional to the concentration of antibodies in the sample.
Target Type Antibody

Origin of standards: human plasma
Number of standards: 3

Plate Pre-coated
Restrictions For Research Use only
Did you look for something else?